Aytu BioScience, Inc. (AYTU - Free Report) will provide corporate and pipeline updates when it reports fourth-quarter fiscal 2020 results.
The company has a mixed earnings surprise history, beating expectations in two of the trailing four quarters and missing in the other two. The average four-quarter negative earnings surprise is 38.35%. In the last reported quarter, the company delivered an earnings surprise of 61.54%.
Shares of Aytu have increased 46% in the year so far compared with the industry’s growth of 6.6%.
Let's see how things are shaping up for this announcement.
Factors to Consider
Aytu reports revenues from two segments — the Rx Business and the Consumer Health Business.
The company recorded highest revenue in the third quarter. Aytu acquired The Innovus Pharmaceuticals in February 2020 to expand its portfolio. The company is likely to have generated significant revenues from this business in the fourth quarter.
In the Rx business, the company expects to see a short-term impact of COVID-19 on its prescription sales. The expected COVID-19 rapid test sales are likely to have more than supplemented its prescription revenues in the fourth quarter.
During the third quarter, the company acquired the distribution rights to COVID-19 rapid test and subsequent to the end of the market quarter began distributing the test in the United States. Following the third quarter, it acquired the distribution rights to a second COVID-19 rapid test from Singapore-based Biolidics. Revenues from these tests are likely to have contributed tothe fourth-quarter performance.
What Our Model Indicates
Our proven model does not conclusively predict an earnings beat for Aytu this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below.
Earnings ESP: Aytu has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a profit of a cent. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #3.
Stocks to Consider
Here are some biotech stocks that have the right mix of elements to beat on earnings this time around:
ACADIA Pharmaceuticals Inc. (ACAD - Free Report) has an Earnings ESP of +4.23% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
bluebird bio Inc. (BLUE - Free Report) has an Earnings ESP of +69.18% and a Zacks Rank of 3.
Amarin Corporation Plc. (AMRN - Free Report) has an Earnings ESP of +72.73% and is Zacks #3 Ranked.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>